Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic drug monitoring-guided tocilizumab dose reduction in rheumatoid arthritis
MOH_2018-11-06_004738Phase 4Completed
- Sponsor
- ד"ר אורי ארד
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tocilizumab in rheumatoid arthritis (RA) (3 arms), sponsored by ד"ר אורי ארד. Primary endpoint: Disease activity assessment. Started Nov 2018; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on MOH_2018-11-06_004738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-06_004738.